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Abstract 
Introduction: Currently, much attention is paid to the pleiotropic effects of 
entretenimiento. 
Purposes: Study of the protective effect exenatide and valdiation with pharmacological 
correction of ischemic myocardial damage, damage of liver and skin graft during the 
experiment. 
Methods: During the experimental study we used a comprehensive approach to the 
study of the antiischemic effects of entretenimento: doksorubitsinola model of 
cardiomyopathy, hypo/reperfusion of the isolated heart, ischemia/reperfusion of the 
liver and the modeling of the skin flap on the supply leg. 
Results and discussion: Exenatide (10 mcg/kg/day) and vildagliptin (0.2 mg/kg/day) 
demonstrate a cardioprotective effect on doxorubicinol model of pathology that is 
reflected in the decline in the rate of diastolic dysfunction (StТТI), respectively, to 
5.3±0.1 standard units. and 6.5±0.2 standart units in comparison with the control group 
8.3±0.1 standart units in the model hypo/reperfusion of the isolated hearts of rats, 
exenatide (10
-6
 mol/l) and vildagliptin (10
-4
 mol/l), prevent the decrease of left 
ventricular pressure (LG). Exenatide (10 µg/kg) and vildagliptin (0.2 mg/kg) prevent 
necrotization of the skin flap 1.5 and 1.3 times in comparison with the control group. In 
the model of ischemia/reperfusion of the liver exenatide possess dose related 
hepatoprotective effect. All protective effects of entretenimiento leveled combined with 
a blocker of ATP-sensitive potassium channels glibenclamide (0.4 mg/kg). 
Conclusion: During the study it was found that exenatide dose of 10 µg/kg/day and 
vildagliptin dose of 0.2 mg/kg, have a pronounced cardioprotective, hepatoprotective, 
and a pronounced cytoprotective effect on a model of isolated skin flap on the supply 
leg. ATP-dependent potassium channels are effector mechanism in the implementation 
of the protective effects of entretenimiento. 
Keywords: entretenimiento, exenatide, vildagliptin, doksorubitsinola cardiomyopathy, 
isolated heart of rats, ischemia. 
 
Introduction 
New substances with cardiotropic effects 
are being identified among various classes of 
chemical and pharmacological groups [1, 2, 3, 
4, 5, 6].Currently aspects of cardiovascular 
safety are a priority when choosing individual 
tactics of patients with type 2 diabetes mellitus 
(T2DM) [7, 8]. It is possible to assume the lack 
of increase of the risk of cardiovascular disease 
(CVD) in patients with T2DM when using 
drugs incretin series[9, 10, 11]. Furthermore, 
the results of experimental and clinical studies 
highlight the potential cardioprotective 
properties of these drugs [12, 13]. 
Accumulated results in recent experimental 
and clinical studies allow to speak about 
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pleiotropic effects of entretenimiento [14]. The 
receptors of GLP-1 are detected in endothelia 
and cardiomyocytes, monocytes, macrophages, 
neurons, bone tissue, adipose tissue and other 
target organs [15, 16]. 
The great interest represents the study of 
cardioprotective and antiischemic effects of 
entretenimiento exenatide and vildagliptin. The 
exact mechanisms underlying their effects on 
different organs and tissues, are still not 
established [13, 15, 17, 18, 19]. The discussed 
effect is the one of ischemic preconditioning, 
where the implementation of effects can be 
done through opening of mitochondrial K-ATP 
channels, which can be a state trigger 
preconditioning [20]. The evidence of the 
activation of antiapoptotic pathways as one of 
the possible mechanisms of the 
cardioprotective effect of early ischemic phase 
of preconditioning are obtained. The most 
likely is the protective effect of peptide growth 
factors including insulin, insulin-like growth 
factor 1, transforming growth factor beta-1, 
cardiotrophin-1 and growth factors of 
fibroblasts, caused by the relatively reperfusion 
injury of the myocardium associated with 
apoptosis through inhibition of P42/P44 MAR-
kinazy and the P13-channals/Аkt-signaling [21, 
22, 23, 24]. The pharmacological 
preconditioning with incrimination can also be 
realized via NO/cGMP-dependent mechanism 
which is also involved in cardioprotective 
effects of entretenimiento [25, 26]. 
It is anticipated that GLP-1 may also have 
a positive impact on oxidative stress and 
endogenous antioxidant defense mechanisms, 
through the increased expression of heme-
oxygenase-1(HO-1) [27, 28], while having a 
positive impact in myocardial cardioprotection 
[29, 30]. 
Purposes: The study of the protective 
effect of pharmacological preconditioning with 
incrimination exenatide and valdiation when 
pharmacological correction of ischemic 
myocardial damage, the damage of liver and 
skin graft in the experiment. 
 
Methods 
The experiments were performed on male 
and female rats of Wistar line weighing 200-
250 g . The experimental animals are obtained 
from the Laboratory animal nursery 
"Stolbovaya" of Governmental Institution The 
Scientific Center of Biomedical Technologies 
Russian Academy of Medical Sciences 
(Moscow region). The contents and their care 
were carried out according to the 
recommendations of State Standard – 53434-
2009 "Principles of good laboratory practice" 
International guidelines "of the European 
Convention for the protection of vertebrate 
animals used for experimental and other 
scientific purposes" (The European 
Convention, 1986). All the experiments were 
approved by the local Ethics Committee 
(Protocol No. 12-2014 dated 21
st
 January 
2015). 
Modeling of doxorubicinol 
cardiomyopathy 
During the simulation of the doxorubicinol 
cardiomyopathy, all the rats were divided into 4 
experimental groups of 10 animals. The first 
group (n=10) the  control one, which was 
injected intraperitoneally with physiological 
solution. The second group (n=10) was injected 
intraperitoneally with doxorubicin (Teva) in a 
cumulative dose of 20 mg/kg, once. The third 
one (n=10) was injected doxorubicin and 
intraperitoneal vildagliptin ("Galvus", Novartis, 
Switzerland) at a dose of 0.2 mg/kg/day. The 
fourth group (n=10) was injected doxorubicin 
and exenatide subcutaneously once per day 
("Beta", Eli Lilly and Company, USA) at a 
dose of 10 mg/kg/day. The doses were 
calculated considering the coefficient of 
interspecies transfer of doses of the human 
body on the body of the rat. Animals were 
taken out from experiment after 48 hours. Their 
hearts were removed under zolotilova 
anesthesia (30 mg/kg) and placed in the ice (2-
4°C) solution of Krebs-Henseleit the following 
composition (mmol): NaCl 118.5; KCl – 4.7; 
MgSO4/7Н2О – 1.2; KH2PO4 – 1.2; CaCl2 – 
1.5; glucose, 11.1; NaHCO3 -25.0. The pH of 
the solution during the whole experiment was 
7.4. The aorta of the heart was coulibalied and 
produced by retrograde perfusion of the heart 
method of Langendorff in the mode of flow 
perfusion for 20 min with a solution of Krebs-
Henseleit, saturated with Carbogen (95 % O2 + 
5% CO2) at 37°C and at a pressure of 100 mm 
Hg and speed perfusate 10 ml/min. The 
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contractile function of the heart was recorded 
with the help of the inserted into the cavity of 
the left ventricle a latex balloon connected to a 
pressure sensor embedded in the device for 
physiological studies МР150 company 
"BiopacSystems, Inc" (California, USA). The 
balloon was filled with distilled water, the 
volume of which was sufficient to create end-
diastolic pressure in the left ventricle at the 
level of 3-5 mm Hg. Using the original 
software program, AcqKnowledge company 
"BiopacSystems, Inc" (California, USA), all 
rats were checked for the indices of 
contractility: left ventricular pressure (LG, mm 
Hg), heart rate (HR, beats/min), the maximum 
rate of contraction (+dp/dtmax, mm Hg/sec), 
the maximum speed of myocardial relaxation (-
dp/dtmax, mm Hg.St./sec). To create a high 
frequency (480 beats/min.) a connector (ground 
electrical stimulator) was attached to a to the 
metallic cannula, and a left atrial appendage 
was joined by a connector. After 20 minutes of 
perfusion with a solution with a high content of 
Ca
2+
(5 mmol/l), the heart was subjected to 
electrical stimulation pulses using the STM 
device 200-1 of the company "BiopacSystems, 
Inc" (California, USA) for 15 seconds. 
To assess the functionality of the 
myocardium, the diastolic dysfunction ratio or 
"diastole defect" (StTTI) calculated from the 
intraventricular pressure curve was used. The 
area under the curve was calculated by folding 
the trapezium areas, which is equal to the 
product of its height on the middle line. 
"diastole defect" (StTTI) expressed in the us 
[31]. 
Integrated assessment of myocardial 
damage in doxorubicinol cardiomyopathy in 
animals have identified the isoenzyme CPK 
(CPK-MB) and lactate dehydrogenase (LDH). 
The activity of lipid peroxidation (LPO) was 
evaluated by the content of malondialdehyde 
(MDA), diene conjugates (DC). 
Hypo-reperfusion in isolated heart of 
rats 
In еру experiments on perfused according 
to Langendorf isolated rats‘ hearts we 
simulated hypo – and reperfusion injury 
(hypoperfusion a 10 – fold decrease in 
perfusion with normal content of Ca2+ (2.5 
mmol/l) [32]. It was judged about the damaging 
effect by the dynamics of indices of 
contractility and reperfusion fibrilace. 
Hepatotropic antiischemic activity 
The study of hepatotropic antiischemic 
activity entretenimiento was carried out in 
anesthetized animals, performing median 
laparotomy on the white line of the abdomen. 
Ischemia was simulated for 15 minutes. After 
that, the contents of the abdomen were laid 
back, and the operative wound was sutured in 
layers. The animals for 3 days were 
administered exenatide (10 mcg/kg/day) and 
vildagliptin (0.2 mg/kg/day) control group with 
0.9 % solution of sodium chloride 
intraperitoneally. 
At the end of 3 days after the experiment 
the animals were euthanized with subsequent 
blood sampling from the heart for biochemical 
analysis and selection of the whole liver to 
conduct morphological analysis. To assess the 
liver function there were chosen biochemical 
markers of damage to hepatocytes of ALT and 
AST. To assess structural changes there were 
made histological sections of specimens of 
liver of the experimental rats with subsequent 
morphological assessment [33]. 
Modeling of the skin flap on the supply 
leg 
The possibility of optimizing the survival 
of the tissues was investigated in a model of 
isolated skin flap on the supply leg. All animals 
were performed the modeling of the skin flap 
on the leg on the second day of the experiment. 
After anesthesia the animals were fixed in 
supine position. The hair on the abdomen was 
carefully cut out, the skin was treated with 70% 
solution of ethyl alcohol. Margins of 1 cm from 
the xiphoid process on the white line of the 
abdomen, made the skin flap 1cm – base, 4 cm 
long, (keeping the supply vessel) insulated in a 
plastic bag, the edges of the skin sutured with a 
continuous suture. The estimation of the area of 
the surviving tissue was performed 
planimetrically on the fifth day. Further we 
calculated the survival rate (ratio of the area of 
the surviving fabric to the original square flap 
×100%) [34]. 
 
Results and Discussion 
Dynamics of functional, biochemical and 
morphological indicators in the simulation 
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doxorubicinol cardiomyopathy, 
hypo/reperfusion of the isolated heart, 
ischemia/reperfusion of the liver and the 
modeling of the skin flap on the supply leg 
For the evaluation of cardioprotective 
actions of pharmacological agents, including 
the modeling of the pathology of 
cardiomyopathy by administration of 
doxorubicin intraperitoneally at a dose of 20 
mg/kg, 48 hours later, the assessment of 
parameters of left ventricular contractility in 
conditions of high rate reductions 480 beats per 
minute for 15 seconds on the background of 
increasing concentrations of Ca2+ and 5 mmol 
in perfusate on the isolated heart of rats as an 
additional criterion of assessment of 
cardioprotective actions of drugs used ratio 
StТТI reflecting"defect diastole" area under the 
curve of the rise of end-diastolic pressure. 
While intact rats have StTTI is 1.4±0.1 standard 
units, and in rats with modeling of the 
pathology of 8.3±0.3 standard units  
(Fig 1.) 
 
 
a 
 
b 
Fig. 1. Dynamics of pressure in the left ventricle (mm. Hg.) with the imposition of rapid heart rhythm 
contractions (480 BPM) for 15 seconds. The concentration of Ca
2+
 in perfusate 5 mmol/L. 
 Intact group (a), doxorubicin (20 mg/kg) (b) 
 
 
The fundamental difference in the area 
under the curve of the rise of end-diastolic 
pressure in the intact group and the control on 
the background of doxorubicin, naturally led to 
the necessity of introducing a factor StТТI, 
which is quite revealing and informative. 
For a comprehensive evaluation of 
myocardial damage it was determined by the 
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isoenzyme CPK (CPK-MB) and lactate 
dehydrogenase (LDH). The activity of lipid 
peroxidation (LPO) was evaluated by the 
content of malondialdehyde (MDA), diene 
conjugates (DC) (fig. 2). 
 
 
 
 
Fig. 2. The content of creatine phosphokinase CPK-MB, LDH, MDA, DK, in the model 
gypo/reperfusion in isolated hearts of rats. 
Note: * p< 0.05 compared with control.** – p< 0.05 compared with intact animals 
 
Investigation of the stability of the 
myocardium to ischemia/reperfusion damage 
were studied on the model of gypo/reperfusion 
in isolated heart of rats under register pressure 
in the left ventricle (LG). In studying the 
cardioprotective activity in the model Hypo-
and reperfusion was discovered that a decrease 
in perfusion in 10 times (coronary 
hypoperfusion) occurs a marked drop in heart 
rate and contractility indices during the first 
5min.By the 20th min of hypoperfusion HR, 
LR,+dP/dtmax, -dP/dtmax were below the initial 
values. Restore the original volume of 
perfusion (reperfusion) was accompanied by 
the development of reperfusion arrhythmias 
that in 3 cases out of 10 lead to fibrillation. 
At the 5th min of reperfusion LG, 
+dP/dtmax, -dP/dtmax remained below the initial 
level. A similar falling trend in the parameters 
of contractility was preserved and further to the 
20th min of reperfusion, where LG, +dP/dtmax, 
-dP/dtmax were less than half the initial value 
(tab. 1). 
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In the simulation laparotomy, there were 
statistically significant indicators of liver 
enzyme values. The imposition of a 15-minute 
ischemia with subsequent reperfusion of the 
liver statistically significantly raised levels of 
transaminases in average 5 times (tab. 2). 
Table 1 
Functional parameters of myocardium in gypo/reperfusion in isolated heart of rats  
(%of initial level) (M±m; n=10) 
 
Indicators The outcome 
Hypoperfusion time Reperfusion time 
5 minutes 20 minutes 5 minutes 20 minutes 
Heart rate, heartbeats 
per min 
224.3±8.4 -64.6±3.2 -58.3±2.3 -16.6±10.3 -10.8±16.1 
LG, mm Hg. 120.0±9.8 -65.8±7.5 -69.3±9.1 -19.8±8.1 -19.5±14.1 
+ dp/dtmax, mm Hg. 2498±4.7 -76.7±2.5 -78.8±1.5 -19.8±14.1 -15.0±19.0 
- dp/dtmax, mm Hg. -1346±1.8 -71.6±2.0 -74.8±10.2 -36.6±10.4 -55.2±12.1 
Note: LG – left ventricular pressure (mm. Hg.); +dp/dtmax maximal rate of reduction (mm 
Hg/sec); -dp/dtmax maximal rate of relaxation (mm Hg/h); HR – heart rate (beats/min).* – p<0.05 in 
comparison with the control group. 
Table 2 
Indicators of the level of transaminases in the simulation of Ieremii/reperfusion 
 of the liver (U/l) (M±m; n=10) 
Group of animals ALT AST 
Intact 68.1±13.8** 102.8±8.9** 
Lineameriloan 72.8±12.3** 110.2±10.3** 
Control 216.9±16.8*1 189.1±13.2*1 
Note: *–p < 0.05 compared with the group of intact animals; **– p < 0.05 in comparison with the 
false-operated group; 1– p>0,05 in comparison with the control group. 
 
According to the study design, the 
assessment of the degree of survival of the skin 
flap on the leg was performed at 3, 7, 10 a day, 
then planimetrically after Avtandilov, 
measuring the area of surviving tissue. Further 
we calculated the survival rate (ratio of the area 
of the surviving fabric to the original square 
flap 100 %. The result revealed that the area of 
necrosis on the 10 day increases by 2.5 times 
(table. 3). 
Table 3 
Survival rates of the isolated skin flap on the supply leg at 3, 7, 10 days after its modeling. 
(M±m; n=10) 
Drugs and their 
dosages 
The area of necrosis KL, % 
3 day 7 day 10 day 
Saline (Control) 30.98±2.84 65.76±2.64 84.55±3.23 
Note:* – p<0,05 in comparison with the control group 
 
Thus, doksorubitsinola model of 
cardiomyopathy, Hypo/reperfusion in isolated 
hearts of rats, ischemia/reperfusion of the liver 
and the modeling of the skin flap on the supply 
leg are easily repeatable and informative 
models to assess of protective effects of drugs 
in ischemic tissues. 
2. The study of cardioprotective, 
hepatoprotective, and cytoprotective effect 
in the model of isolated skin flap on the 
supply leg from exenatide and vildagliptin 
Entretenimiento exenatide at doses  
(1 mg/kg/day and 10 mg/kg/day) and 
vildagliptin (0.02 and 0.2 mg/kg/day) did not 
affect the degree of decrease of contractility 
(table. 4). 
However, dose-dependently we prevented 
the decrease in contractility during the tests 
 Tarasova A.P., Danilenko L.M., Sernov L.N.  Effect of pharmacological preconditioning with 
incretinomimetics exenatide and vildagliptin on the survival of ischemic tissues. Research 
Results in Pharmacology. 2017;3(4):132-150. 
138 
 
December. 2017. 3(4). Research Results in Pharmacology rrpharmacology.ru 
with high-frequency stimulation. At the same 
time, StТТI for exenatide 10 µg/kg/day and 
vildagliptin 0.2 mg/kg/day was 5.3±0.1 and 
6.5±0.2 us.ed. respectively (Fig. 3). 
 
Table 4 
The influence of entretenimiento exenatide and vildagliptin on the performance of the contractile 
function of the hearts of rats under doxorubicinol cardiomyopathy (M±m; n=10) 
Groups of animals LG +dp/dtmax -dp/dtmax HR 
IntactAnimals 87.3±9.2* 1423±162.2* -1265.2±173.2* 248±32.1 
Control Doxorubicin 
(20mg/kg) 
64.5±11.2** 1025.7±154.3** -1031.1±159.4** 247±29.4 
Doxorubicin (20mg/kg)+ 
Exenatide (1 µg/kg/day.) 
60.2±9.4** 1165,7±134.3** -1109.9±119.4** 232±29.4 
Doxorubicin(20mg/kg)+ 
Exenatide (10mcg/kg/day.) 
76.8±7.4* 1302±169.2* -1157.4±137.3* 231±26.9 
Doxorubicin (20mg/kg) + 
Vildagliptin(0.02 mg/kg/day.) 
59.1±10.7** 1107,7±15.,3** -984.9±129.1** 227±29.4 
Doxorubicin (20mg/kg)+ 
Vildagliptin (0.2 mg/kg/day.) 
73.2±51* 1219±145.4* -1108±169.3* 232±36.1 
Note: the LG – left ventricular pressure (mm. Hg); +dp/dtmax maximal rate of reduction (mm 
Hg/sec); -dp/dtmax maximal rate of relaxation (mm Hg/h); HR – heart rate (beats/min). Doxorubicin 
was administered intraperitoneally, 48 hours before the experiment. Entretenimiento and vildagliptin 
exenatide were administered twice with an interval of 24 hours, subcutaneously and intraperitoneally, 
respectively, * * p<0.05 compared with the group of intact animals;* – p<0.05 in comparison with 
control group. 
 
 
Fig. 3. The impact exenatide (10 mg/kg/day) and vildagliptin (0.2 mg/kg/day) for the coefficient  
of diastolic dysfunction (StТТI), with doxorubicinol cardiomyopathy. 
Note: ** p<0.05 compared with the group of intact animals; 
* – p<0.05 in comparison with control group 
 
The values StТТI for exenatide at a dose of 1 
mcg/kg/day and vildagliptin 0.02 mg/kg/day were 
not significantly different from the control group. 
During the study of cardioprotective 
activity of incrimination on the model of 
Hypo/reperfusion it discovered that the addition 
of perfusiology solution exenatide at a dose of 
10
-6
 mmol/l and vildagliptin 10
-4
 mmol/l, 
statistically znachimyh changes LG, +dP/dtmax, 
-dP/dtmax and heart rate in the period of 
hypoperfusion to 20 min in comparison with 
the control was not detected. In the period of 
reperfusion, both entretenimiento prevented the 
fall in contractility and on the 5th and 20th min 
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differed little from the original values, whereas 
in control, they fell by more than 50% (tab. 5). 
In addition, unlike the control, the number of 
reperfusion arrhythmias decreased markedly. 
Table 5 
Cardioprotective action exenatide (10
-6
 mmol/l) and vildagliptin (10
-4
 mmol/l) with Hypo-
reperfusion in isolated heart of rats (%of initial level)(M±m; n=10) 
Indicators 
Group of 
animals 
Outcome 
Hypoperfusion time Reperfusion time 
5 minutes 20 minutes 5 minutes 20 minutes 
Heart rate, 
heartbeats 
per min 
Control 224.3±8.4 -64.6±7.2 -58.3±8.3 -16.6±10.3 -10.8±14.1 
Exenatide 233.0±7.3 -3.2±6.4* -53.5±5.3 +1.4±9.1* +2.8±13.7 * 
Vildagliptin 221.3±7.8 -45.3±4.9 * -54.6±7.2 -8.9±6.2* -3.2±9.1 * 
LG, mm Hg Control 120.0±9.8 -65.8±7.5 -69.3±9.1 -19.8±8.1 -19.5±14.1 
Exenatide 116.8±7.1 -78.7±9.3 -62.6±8.8 -8.1±10.2* -1.8±11.2* 
Vildagliptin 114.0±11.1 -67.0±8.7 -61.1±9.2 -6.4±9.4 * -1.4±10.0* 
+ dp/dtmax, 
mm Hg 
Control 2498±4.7 -76.7±2.5 -78.8±6.5 -19.8±11.1 -15.0±12.0 
Exenatide 2309±7,5 -77.6±7.9 -75.7±10.1 -12.9±9.4* +5.4±9.2* 
Vildagliptin 2325±6.9 -78.6±9.4 -76.8±5.5 -10.8±8.8* +3.5±8.7* 
- dp/dtmax, 
mm Hg 
Control 1346±1.8 -71.6±5.0 -74.8±10.2 -36.6±10.4 -55.2±12.1 
Exenatide 1345±2.4 -69.1±9.7 -69.6±9.2* -12.9±7.9* +3.7±11.0* 
Vildagliptin 1265±5.7 -67.3±6.8 -70.5±7.4 -10.8±9.4* +4.5±7.9* 
Note: The LG – left ventricular pressure (mm. Hg.St); +dp/dtmax maximal rate of reduction (mm 
Hg./sec); -dp/dtmax maximal rate of relaxation (mm Hg./h); HR – heart rate (beats/min).* – p<0,05 in 
comparison with the control group. 
 
The ability of exenatide 10 µg/kg/day and 
vildagliptin 0.2 mg/kg/day to prevent damage 
to cell membranes was estimated by the change 
in the activity of ck-MB and LDH. Exenatide 
and vildagliptin contributed to the decline in 
levels of creatine kinase-MB by 27% and 19% 
and LDH of 11.8% and 9.6% relative to the 
control group (figure 4). 
 
 
Fig. 4. The content of creatine phosphokinase CPK-MB and LDH in groups with exenatide  
(10 mg/kg/day.) and vildagliptin (0.2 mg/kg/day). 
Note: ** p<0.05 compared with the group of intact animals; 
* – p<0.05 in comparison with control group
Similar changes were detected in the 
marker of the products of lipid peroxidation 
(figure 5).  
The correction of the ischemic liver 
damage by exenatide (10 mg/kg/day) and 
vildagliptin (0.2 mg/kg) reduces the level of 
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transaminases in 2 times, however, does not restore values to the original level (table 6).
 
  
Fig. 5. The contents of MDA and DC in homogenate in groups with exenatide (10 mg/kg/day.) and 
vildagliptin (0.2 mg/kg/day) 
Note: ** p<0.05 compared with the group of intact animals; 
* – p<0.05 in comparison with control group 
 
Table 6 
Indicators of the level of transaminases in modeling of schemia/reperfusion of the liver (U/l) 
(M±m; n=10) 
 
Group of animals ALT AST 
Intact 102.89±8.9** 68.1±13.8** 
Lineameriloan 110.2±10.3** 72.8±12.3** 
Control 189.1±13.2*1 216.9±16.8*1 
Exenatide (10 µg/kg/day) 130.2±10.9** 107.1±11.7** 
Vildagliptin (0.2 mg/kg) 157.2±11.4** 145.8±13.4** 
Note: *– p < 0.05 compared with the group of intact animals; **– p<0,05 in comparison with the 
false-operated group; 
1
 – p<0,05 in comparison with the control group. 
 
The same trend is confirmed by the 
morphological picture of the liver (figure 6). 
When modeling the skin flap on the supply 
leg, both studied entretenimiento contributed to 
the reliable correction to increase the area of 
surviving tissue in comparison with the control 
group at 3, 7 and 10 day. In the control group, 
the amount of necrosis amounted to 
84.55±3.23%, in the group with exenatide and 
vildagliptin 63.18±2.42 and 76.08±2.53, 
respectively.
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a                                                                                  b 
Fig. 6. Morphological picture of the liver in a series of false-operated animals (a) and control group (b) 
micro photos. X400 
 
Thus, on the totality of functional, 
biochemical and morphological indicators, 
entretenimiento exenatide (10 mg/kg/day) and 
vildagliptin (0.2 mg/kg) has a pronounced 
cardioprotective, hepatoprotective, and 
cytoprotective effects on the studied models of 
pathologies. 
3. Defining of the role of ATP dependent 
potassium channels in the implementation of 
the protective effects of entretenimiento 
The most likely effector link cytoprotective 
in the phenomenon of ischemic preconditioning 
are the ATP-dependent potassium channels. 
The prior blockade of the ATP-sensitive 
potassium channels using intraperitoneal 
injection of glibenclamide dose of 5 mg/kg on 
the background modeling of the doxorubicinol 
cardiomyopathy, applications exenatide and 
vildagliptin led to the leveling effects of 
cardioprotection. The ratio of diastolic 
dysfunction StTTI in the group of animals 
treated with glibenclamide and exenatide and 
vildagliptin weren‘t significantly different from 
the control group and amounted to 7.5±0.6 and 
7.9±0.7 standard unit (figure 7). 
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Fig. 7. The impact of the exenatide and vildagliptin on a factor of diastolic dysfunction 
(StТТI), with doxorubicinol cardiomyopathy. 
Note: ** p<0.05 compared with the group of intact animals; 
* – p<0.05 in comparison with control group 
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Cardioprotective effects of incrimination 
were leveled with the introduction of the 
perfusate glibenclamide (10-6ммоль) fashion 
Hypo/reperfusion in isolated hearts of rats. The 
level of biochemical markers and products of 
lipid peroxidation didn‘t reduce (figure 8).
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Fig. 8. The content of CPK-MB, LDH, MDA, DK in the exenatide group (10 mg/kg/day.)  
and vildagliptin (0.2 mg/kg/day) in the model of Hypo/reperfusion in isolated hearts of rats. 
Note: ** p<0.05 compared with the group of intact animals; 
* – p<0.05 in comparison with control group 
 
Entretenimento didn‘t show the 
pronounced hepatoprotective actions in the pre-
blockade of ATP-sensitive potassium channels. 
The values of ALT and AST is comparable to 
the control group. That shows the lack of effect 
on the background of administration of 
glibenclamide (5 mg/kg) (table 7). 
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Table 7 
Protective action of exenatide and vildagliptin on transminase on the background  
of glibenclamide during ischemia/reperfusion of the liver (U/l). (M±m; n=10) 
Group of animals ALT AST 
Intact 68.1±13.8** 102.89±8.9** 
Lineameriloan 72.8±12.3** 110.2±10.3** 
Control 216.9±16.8*1 189.1±13.2*1 
Exenatide 10 µg/kg/day 
130.2±10.9** 
 
127.1±11.7** 
 
Exenatide 10мкг/kg/day 
+Glibenclamide 0.4 mg/kg 
211.3±15.1** 
 
175.6±13.2** 
 
Vildagliptin 0.2 mg/kg 
157.2±11.4** 
 
145.8±13.4** 
 
Vildagliptin 0.2 mg/kg+ 
Glibenclamide 0.4 mg/kg 
202.90±16.9 
 
169.4±8.1 
 
Note: *–p < 0.05 compared with the group of intact animals; **– p<0.05 in comparison with the 
false-operated group; 
1
 – p<0.05 in comparison with the control group. 
 
The prior blockade of ATP-sensitive 
potassium channels, completely negate the 
protective effect of entretenimiento when 
modeling of a skin graft on feeding pedicle  
in rats. 
 
Table 8 
Protective action of exenatide and vildagliptin on the background  
of glibenclamide survival of skin graft (%). (M±m; n=10) 
 
Drugs and their dosages 
The area of necrosis KL, % 
3 day 7 day 10 day 
Saline (control) 30.98±2.84 65.76±2.64 84.55±3.23 
Exenatide (10 µg/kg/day) 24.37±3.12* 44.13±3.15* 63.18±2.42* 
Exenatide (10мкг/kg/day) 
+ Glibenclamide (0.4 
mg/kg) 
29.18±2.04 59.16±2.53 81.35±3.20 
Vildagliptin (0.2 mg/kg) 26.10±2.83* 52.19±3.00* 76.08±2.53* 
Vildagliptin (0.2 mg/kg) + 
Glibenclamide (0.4 mg/kg) 
33.22±2.12 60.71±2.59 83.51±3.13 
Note: *- p<0.05 in comparison with the control group 
 
Nowadays, there is a large amount of data 
on the impact of GLP-1 and DPP on the 
cardiovascular system and various organs and 
tissues, the mechanisms of these effects differ 
from those mediated by the decrease of 
glycemia. The receptors of GLP-1 are widely 
represented in the body and, in addition to 
gastrointestinal tract, nervous system, lungs, 
kidneys, lymphocytes were found also in 
vascular smooth muscle cells, cardiomyocytes, 
endocardium and endothelial cells, which 
became the basis for the study of its 
cardiovascular effects [35, 36]. The receptors 
of GLP-1 (along with receptors for glucagon, 
secretin, calcitonin, somatoliberin, parathyroid 
hormone, vasointestinal peptide) belong to the 
class of the family of receptors associated with 
G-proteins (GCPR) [37]. In terms of the 
damage of ischemia—reperfusion 
cytoprotection is mainly due to the anti-
apoptotic effect. GLP-1 binding to the receptor, 
suppresses apoptosis of β-cells and 
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cardiomyocytes, by activating the formation of 
camp and fashionsitas-3-kinase (PI3-K) [38]. 
The activation of the RISK kinases 
(Reperfusion InjurySalvage Kinase), which 
includes PI3K and extracellular signal-
regulated kinase (ERK 1/2). GLP-1 activates 
the serine-treoninove kinase (Akt). Favorable 
cardiotropic action of Akt is due to its ability to 
inhibit the processes of cell death of 
cardiomyocytes and to improve the survival 
rate of myocardial cells subjected to ischemia 
[39]. GLP-1 activates antioxidant gene 
hemeoxygenase-1 (HO-1). This enzyme 
prevents the heme catalyzed formation of 
highly reactive hydroxyl radicals from 
hydrogen peroxide. Activation of heme-
oxygenase-1 is associated with increased 
catabolism of heme to bile pigments, which are 
potential endogenous antioxidants. In addition, 
the induction of heme-oxygenase-1 is 
accompanied by increased activity of ferritin, 
which has antiapoptotic effect. The increase in 
expression of heme-oxygenase-1 in conditions 
of oxidative stress may play an adaptive role in 
response to oxidative damage and reduce the 
loss of cardiomyocytes. In experimental studies 
it is shown that the modeling of the 
doxorubicin cardiomyopathy in transgenic mice 
and animals with excessive expression of HO-1 
and cardiac-specific overexpression of HO-1 
prevents doxorubicin-mediated damage to the 
sarcoplasmic reticulum and mitochondria in 
automagically the vacuoles [28]. 
Overexpression of HO-1 contributes to 
mitochondrial biogenesis by increasing protein 
expression of nuclear respiratory factor 
(NRF1), coactivator (PGC1α) and 
mitochondrial transcription factor (TFAM), 
which is inhibited in transgenic animals with 
doxorubicinol cardiomiopatia [40, 41]. 
Concurrently, overexpression of HO-1 inhibits 
the amplification of mitochondrial mediator of 
fission (Fis1) and leads to increased expression 
of mediators of synthesis of Mfn1 and Mfn2. It 
also prevents mutations in key genes of 
mitochondrial PINK1 and PARKIN and 
ensures their normal operation. This proves that 
the BUT-1 plays an important role in protecting 
heart from oxidative damage affecting the 
mitochondria . HO-1 is a protective antioxidant 
enzyme that acts through the induction of gene 
expression of nuclear transcription factor Nrf2, 
resulting in activation of Akt [42, 43]. 
Also, it is assumed that the positive effects 
of GLP-1 on myocardium may be due to 
activation of other signaling pathways (GSK3β, 
a family of proteins Bcl-2), and also due to the 
favorable effects of PPARs-β and -δ [43]. 
Cardioprotective effect of GLP-1 can be carried 
out through receptor-independent mechanisms. 
It is assumed that previously considered 
biologically inactive primary metabolite GLP-1 
produced after interaction with DPP-4 and 
having a very low affinity to the receptor GLP-
1 also plays a cytoprotective role by inhibiting 
the processes of cell death in cardiomyocytes in 
conditions of damage of ischemia (reperfusion 
through PI3 and ERK 1/2-dependent). The 
exact mechanisms of the effect of GLP-1 in 
ischemic injury remain unclear. One of them 
may be a direct stimulation of the receptors of 
GLP-1 on vascular smooth muscle cells that 
can be due to endothelium-dependent 
vasodilation (due to NO-dependent and NO-
independent mechanisms)  signaling pathways 
[44, 45].  
Finally, the implementation of the 
protective effect of entretenimiento suggests 
mechanisms by type of ischemic 
preconditioning. End-effector link which can 
be considered as a mitochondrial ATP are the 
dependent potassium channels, whose 
activation leads directly to the increased 
resistance of the myocardium to ischemia. In 
addition, the experimental work of the last 
years showed that the cardioprotective effect of 
preconditioning can be completely (!) 
eliminated with the introduction of the RISK 
inhibitors of kinases (specifically ERK1/2 and 
PI3K), carried out during the initial period of 
reperfusion after the prolonged ischemia [46, 
47, 48].  
Hypothetical model of the mechanism of 
action of entretenimiento is presented in figure 
9. 
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Fig. 9. Schematic representation of the proposed pathways by which GLP-1 may exert its 
cardiovascular actions. The combination of GLP-1 effects on the myocardium (i.e. apoptosis and 
necrosis prevention in cardiomyocytes through the activation of the RISK pathway, increased glucose 
metabolism, vasodilatory and anti-inflammatory actions) with GLP-1 metabolic and vascular effects  
at the systemic level contributes to cardiac survival and function improvement  
 
Note: cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate;  
Cyt c, cytochrome c; DPP-4, dipeptidyl peptidase-4; ERK, extracellular signal-regulated kinase; 
GLUT, glucose transporter; GSK, glycogen synthase kinase; LDH, lactate dehydrogenase; MEK1/2, 
MAP kinase kinase; MPTP, mitochondrial permeability transition pore; NOS, nitric oxide synthase; 
PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKB, protein kinase B; ROS, reactive 
oxygen species 
 
However, the effects on the receptors  
GLP-1 and inhibition of DPP-4 require the 
further study. 
Conclusion 
Thus, in the course of the study it was 
revealed that doksorubitsinola cardiomyopathy 
(20 mg/kg, intraperitoneally for 48 hours) leads 
to the development of «the defect of diastole» 
increasing the area under the curve of left 
ventricular pressure 8 times. gypo/reperfusion 
(10:1, 20 min) in isolated hearts of rats leads to 
a decrease in LG by 2 times. Ischemia 
/reperfusion of the liver (15 min) leads to an 
increase in transaminases for 5 times (ALT and 
AST) and the characteristic dynamics of 
morphological patterns. The survival rate of 
skin flap on the leg are, respectively, 50, 60 and 
70%. The proposed methods allow to provide a 
comprehensive evaluation of effects of 
pharmacological agents on the survival of 
ischemic tissues. Exenatide (10 µg/kg) and 
vildagliptin (0.2 mg/kg) exert a 
cardioprotective effect in the models of 
doxorubicinol cardiomyopathy, expressed in a 
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reduction factor of diastolic dysfunction StTTI to 
values of 5.3±0.1 and 6.5±0.2 standard units 
respectively. In the model of gypo/reperfusion 
in isolated hearts of rats, exenatide (10
-6
 mol/l) 
and vildagliptin (10
-4
 mol/l) have a 
cardioprotective effect. Exenatide (10
-6
 mol/l) 
shows the most pronounced effect. Exenatide 
(10 µg/kg) and vildagliptin (0.2 mg/kg) prevent 
the necrotization of the skin flap in 1.7 and 1.5 
times in comparison with the control group. In 
the model of ischemia/reperfusion of the liver 
exenatide (10 µg/kg) and vildagliptin  
(0.2 mg/kg) possess the dose related 
hepatoprotective effect, resulting the prevention 
of the increase of ALT and AST, and the 
morphological picture of the liver changes in 
the same way. All the protective effects of the 
exenatide (10 µg/kg) and vildagliptin (0.2 
mg/kg) were neutralized in a joint application 
with a blocker of ATP-sensitive potassium 
glibenclamide channels (0.4 mg/kg). 
Consequently, ATP-dependent potassium 
channels may be the effector mechanism in the 
implementation of the protective effects of 
entretenimiento. NO acts as a trigger of 
ischemic preconditioning. 
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